№ files_lp_4_process_3_126935
File format: docx
Character count: 21751
File size: 61 KB
Year:
2024
Location:
Harare, Zimbabwe
Study type:
Cross-sectional hospital study
Subject:
Pediatric acute leukemia
Sample size:
44 patients
Age range:
0–17 years
Sex distribution:
26 female, 18 male
Leukemia subtype:
AML 56.8%, ALL 43.2%
Genetic factors:
Down syndrome 13.6%, Neurofibromatosis 20.5%
Haematological abnormalities:
Anaemia 80%, Thrombocytopenia 78%, Low RBC count 70%, Leukocytosis 60%
Treatment follow-up:
Persistent cytopenias during chemotherapy
Institution:
Parirenyatwa Group of Hospitals
Data collection period:
January–September 2024
Clinical parameters:
Hemoglobin, platelet count, RBC and WBC counts, MRD levels where available
Analytical tools:
SPSS v26, descriptive statistics, chi-square and t-tests
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / City:
North Central Nigeria
Topic:
Blood transfusion, biochemical changes, hematology
Document Type:
Research Study
Organization:
Faith Alive Foundation Jos
Author:
Not specified
Target Audience:
Researchers, healthcare professionals, medical practitioners
Period of Validity:
35 days of blood storage
Approval Date:
Not specified
Modification Date:
Not specified
Keywords:
Blood, Transfusion, Biochemical, Haematological, CPDA
Context:
The document presents a pilot study on biochemical and haematological changes in blood stored in CPDA, aiming to understand the impact of storage on blood components and the associated risks in transfusion practice.
Year:
2025
Region / city:
Rawalpindi, Pakistan
Topic:
Hematology, Thromboembolic Events, COVID-19
Document type:
Research Article
Institution:
Benazir Bhutto Hospital
Authors:
Nabil Ahmad, Ahsan Bhatti, Noshaba Mohmand, Raees Khan
Target audience:
Healthcare professionals, researchers
Period of validity:
2025
Approval date:
Jul 20, 2025
Date of revisions:
Jul 01, 2025
Date of receipt:
Apr 17, 2025
Available online date:
Sep 02, 2025
Year:
2023
Region / city:
Egypt
Theme:
Veterinary medicine, reproductive efficiency
Document type:
Research article
Institution:
Faculty of veterinary medicine, Benha University
Author:
M.A. Aboulroos, G.A. Sosa, A.M.S. Mostafa, M.A. Agag
Target audience:
Veterinary professionals, researchers, animal scientists
Period of validity:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
N/A
Topic:
Hematological indices, immunological indices, biochemical indices, lipid indices, and redox status indices of chicken blood
Document type:
Scientific Research
Organization / Institution:
N/A
Author:
N/A
Target audience:
Researchers, scientists in veterinary and poultry science
Validity period:
N/A
Approval date:
N/A
Date of modifications:
N/A
Description:
A scientific data set of various blood indices of chickens at 14 days of age, including hematological, immunological, biochemical, and lipid parameters in different groups such as vaccinated, unvaccinated, and those receiving varying levels of crude protein and herbal extracts.
Year:
2021
Region / City:
Not specified
Theme:
Hematology, Leukemia, Molecular Biology
Document Type:
Research Supplementary Figure
Author:
Not specified
Target Audience:
Researchers in the field of leukemia and hematopoiesis
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Contextual Description
Year:
2000–2022
Study Type:
Clinical research
Patient Population:
ABL-class leukemia patients
Sample Type:
Bone marrow and blood DNA
Assay Methods:
RNA sequencing, targeted locus amplification (TLA), genomic capture high throughput sequencing (gc-HTS), Fusion Detection by Gene Enrichment (FUDGE), long-range PCR, Sanger sequencing
Quantitative Assay:
MRD Q-PCR based on genomic breakpoints and IG/TR targets
Institution:
Princess Máxima Centrum, Netherlands; USEQ sequencing facility, Utrecht, Netherlands; Macrogen Europe
Ethics:
Written informed consent obtained according to the Declaration of Helsinki
Data Tables:
Supplemental Digital Tables 1–3
Figures:
Supplemental Digital Figures 1–2
Reference Protocols:
EuroMRD guidelines
Year:
2015
Region / City:
Southeastern/Southwest United States
Field:
Medicine, Oncology
Document Type:
Abstract
Organization:
Texas Tech University Health Sciences Center, University of Pennsylvania
Author:
Paul Trippier, Kshitij Verma, Tianzhu Zang, Trevor M. Penning
Target Audience:
Researchers, Medical Professionals
Effective Period:
Not specified
Approval Date:
Not specified
Date of Last Update:
Not specified
Year:
Not specified
Disease:
Acute Myeloid Leukemia (AML)
Genetic Focus:
FLT3 mutations (TKD, ITD, ITD-TKD)
Treatment Groups:
FLT3 inhibitors (FLT3i) vs Conventional Chemotherapy (CT)
Endpoints:
Overall Survival (OS); Event-Free Survival (EFS); Time to Transplant
Study Period:
Before and after 2018 approval of FLT3 inhibitors
Statistical Methods:
Logistic regression; Propensity score weighting; Inverse probability weighting; Cox proportional hazard models; Mediation analysis; Sensitivity analysis
Confounders Considered:
Sex; Age; AML type; FLT3 mutation type; White-blood cell count; Platelet count; ELN risk classification; Ongoing comorbidities
Risk Classification System:
European LeukemiaNet (ELN)
Supplementary Material:
Table S1 (subgroup analyses with inverse probability weighting); Table S2 (baseline characteristic survival analyses)
Key Measures:
Hazard Ratios (HR); 95% Confidence Intervals (CI); p-values
Regulatory Milestone Referenced:
Clinical approval of FLT3 inhibitors in 2018
Name:
William D. Marrero-León, MD
Current Position:
Clinical Fellow, Leukemia Fellowship Program
Institution:
The University of Texas MD Anderson Cancer Center
Start Date:
July 2025
Specialty:
Hematology and Medical Oncology
Board Certification:
Internal Medicine; Hematology
Clinical Interests:
Targeted therapies; molecular markers in leukemia treatment
Medical School:
Iberoamerican University School of Medicine
Residency:
Internal Medicine, San Juan City Hospital
Previous Appointment:
Faculty Member, University District Hospital
Additional Training:
Fellowship in Hematology and Medical Oncology, San Juan City Hospital
Leadership Role:
Chief Fellow
Awards:
First Prize in Clinical Research (twice), Puerto Rico Hematology Oncology Convention
Research Focus:
Molecular and cytogenetic abnormalities in acute myeloid leukemia (AML) patients in Puerto Rico
Mentor:
Fernando Cabanillas
Publications:
Two peer-reviewed publications
Year:
2017
Region / City:
N/A
Topic:
Hematologic Toxicities, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Document Type:
Meta-analysis
Organization:
N/A
Author:
N/A
Target Audience:
Researchers, Healthcare Professionals
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
2/2018
Year:
2021
Region / city:
Not specified
Topic:
Mesenchymal cells in bone marrow of AML patients
Document type:
Research Supplementary Data
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, medical professionals
Effective period:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2013–2019
Cell Type:
THP-1 acute myeloid leukemia; Jurkat acute lymphoid leukemia
Treatment:
Apigenin (AP), Etoposide (ETP), Cyclophosphamide (CYCLO)
Assay Method:
Proteome ProfilerTM - Human Apoptosis Array
Measured Proteins:
BAD, BAX, BCL2, BCLX, CYT c, SMAC/DIBALO, HTRA2/OMI, TRAILR1/DR4, TNFR1/TNFRSF1A, FAS/D95, FADD, CASP-3
Exposure Time:
24 hours
Effect Type:
Synergistic increase or decrease in apoptosis-related protein expression
Reference Studies:
Mahbub et al., 2013; 2015; 2019
Data Format:
Supplementary Figures
Year:
2010–2015
Institution:
University Hospitals Case Medical Center
Field:
Biomedical Research / Hematology
Document Type:
Research Methods Supplement
Techniques:
Immunohistochemistry, Flow Cytometry, Multi-photon Intravital Imaging, Chromatin Immunoprecipitation, Luciferase Reporter Assay, Western Blot, qRT-PCR
Model Organisms:
Mice (including leukemia models)
Authors:
Myers JT, Barkauskas DS, Huang AY, Wang W, Yu S, Zimmerman G, Wang Y, Yu VW, Huang D, Huang X, Shim J, Huang Y, Xin W, Qiao P, Yan M, Scadden DT, Stanley P, Lowe JB, Zhou L, Yao D
Target Cells:
Hematopoietic stem cells, marrow stromal cells, leukemia cells
Reagents and Antibodies:
Hes1, RBPJ, JAG1, ICN1, ICN2, GFP, Annexin V, CD41, CXCL12, GAPDH
Culture Conditions:
α-MEM medium, serum-free medium, supplements including mSCF and TPO
Imaging Equipment:
SP5/AOBS/2-photon microscope, Leica Microsystems, Imaris software
Analytical Methods:
qRT-PCR, fluorescence imaging, statistical analysis
References:
Myers JT et al., Stem Cells International 2013; Myers J et al., Transfusion 2010; Wang W et al., Stem Cells 2015; Yao D et al., Blood 2011
Year:
2023
Region / City:
Cambridge, Massachusetts; Denver, Colorado; Philadelphia, Pennsylvania
Subject:
Pinometostat treatment, leukemia research, resistance mechanisms
Document Type:
Research Methods Supplement
Author(s):
Carly T. Campbell, Jessica N. Haladyna, David A. Drubin, Ty M. Thomson, Michael J. Maria, Taylor Yamauchi, Nigel J. Waters, Edward J. Olhava, Roy M. Pollock, Jesse J. Smith, Robert A. Copeland, Stephen J. Blakemore, Kathrin M. Bernt, Scott R. Daigle
Target Audience:
Researchers, biotechnologists, and medical professionals in oncology and pharmacology
Period of Validity:
2023
Approval Date:
2023
Modification Date:
N/A
Methodology:
Sanger sequencing, RNA-seq, ChIP-Seq, Quantitative PCR, Western Blot, Transporter Study
Context:
Detailed supplemental methods and experimental procedures for studying resistance mechanisms to Pinometostat in MLL rearranged leukemia cells, including sequencing, immunoprecipitation, and transporter studies.
Year:
2023
Region / city:
Pittsburgh, PA, U.S.A.
Topic:
Hematology, Oncology, Dermatology
Document type:
Case Report
Institution:
Allegheny General Hospital
Author:
Muhammad Ali Butt, Sameen Aamer, Anastasios Kapetanos
Target audience:
Healthcare professionals, researchers in hematology and oncology
Date of approval:
Not specified
Date of changes:
Not specified
Keywords:
Henoch-Schonlein Purpura, acute myeloid leukemia, cutaneous presentation of acute myeloid leukemia
Abstract:
This document reports an unusual case of Henoch-Schonlein Purpura (HSP) as the presenting symptom of Acute Myeloid Leukemia (AML).
Contextual description:
A case report of a patient who presented with a rash consistent with Henoch-Schonlein Purpura, later diagnosed with Acute Myeloid Leukemia.
Year:
2026
Region:
International
Subject:
Pediatric acute lymphoblastic leukemia
Document type:
Supplemental digital content
Institution:
Multiple international cooperative study groups
Authors:
Østergaard, A et al.
Study groups:
BFM, IC BFM, ANZCHOG, DCOG, NOPHO, UKALL, MB, GBTLI, JACLS, CoALL
Datasets:
A, B, C
Methodology:
MRD-guided protocols and survival analysis
Outcome measures:
Event-free survival, relapse rate, overall survival
Context:
Dataset tables and Kaplan-Meier survival curves evaluating prognostic significance of IKZF1 deletions in childhood acute lymphoblastic leukemia across multiple study protocols
Year:
2023
Region / City:
Not specified
Topic:
Leukemia Cutis, Chronic Myeloid Leukemia
Document Type:
Case Report
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, researchers
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Year
Document Type:
Template
Year:
2014
Region / city:
England
Topic:
Mental Health, Common Mental Disorders, Healthcare Accessibility
Document type:
Research article
Organization / institution:
University College London, Queen Mary University of London, City University of London, National Centre for Social Research
Author:
Alexander T Hiepko, Natalie Shoham, Sally McManus, Claudia Cooper
Target audience:
Researchers, policymakers, healthcare professionals
Period of validity:
2014
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2024
Region / City:
Tlogowungu, Miri
Subject:
Postpartum health, physical activity, quality of life
Document Type:
Research Article
Organization / Institution:
Muhammadiyah University Surakarta
Author:
Qur`ana Fauziyah, Faizah Betty Rahayuningsih
Target Audience:
Health researchers, maternal health professionals
Period of Action:
2024
Approval Date:
Not specified
Date of Changes:
Not specified